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Abstract: (1) Background: The acquisition of multiple chronic diseases, known as multimorbidity,
is common in the elderly population, and it is often treated with the simultaneous consumption
of several prescription drugs, known as polypharmacy. These two concepts are inherently related
and cause an undue burden on the individual. The aim of this study was to identify combined
multimorbidity and polypharmacy patterns for the elderly population in Catalonia. (2) Methods:
A cross-sectional study using electronic health records from 2012 was conducted. A mapping
process was performed linking chronic disease categories to the drug categories indicated for their
treatment. A soft clustering technique was then carried out on the final mapped categories. (3) Results:
916,619 individuals were included, with 93.1% meeting the authors’ criteria for multimorbidity and
49.9% for polypharmacy. A seven-cluster solution was identified: one non-specific (Cluster 1) and six
specific, corresponding to diabetes (Cluster 2), neurological and musculoskeletal, female dominant
(Clusters 3 and 4) and cardiovascular, cerebrovascular and renal diseases (Clusters 5 and 6), and multi-
system diseases (Cluster 7). (4) Conclusions: This study utilized a mapping process combined with a
soft clustering technique to determine combined patterns of multimorbidity and polypharmacy in
the elderly population, identifying overrepresentation in six of the seven clusters with chronic disease
and chronic disease-drug categories. These results could be applied to clinical practice guidelines in
order to better attend to patient needs. This study can serve as the foundation for future longitudinal
regarding relationships between multimorbidity and polypharmacy.
Keywords: multimorbidity; polypharmacy; elderly; primary healthcare; chronic disease; clustering;
combined patterns; machine learning
1. Introduction
The global life expectancy at birth has increased from 52.6 years in 1960 to 72.6 years
in 2018 [1]. While it is certain that people are living longer on average, this does not
necessarily mean they are living healthier lives, as an increase in life expectancy anticipates
an increase in morbidity [2,3]. As individuals age, the body changes and experiences a
state of physical decline, resulting in weaker defenses and easier acquisition of chronic
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illnesses in the later years of life [2,4]. The diagnosis of two or more chronic diseases in the
same individual is referred to as multimorbidity [5].
Multimorbid individuals tend to be prescribed a high number of medications in order
to combat their diagnosed chronic illnesses. Consumption of prescribed drugs holds a
higher prevalence and relevance in older adults, and complications could include po-
tentially inappropriate prescribing [6]. While a homogeneous operational definitional is
lacking throughout the field, literature supports the definition of polypharmacy as the
consumption of five or more drugs daily in the same individual [7]. Polypharmacy is
considered a critical public health problem that is related to drug-drug and drug-disease
interactions, adverse drug events [8–12], falls, hospital admissions and mortality [13,14].
Polypharmacy has been on the rise over the past several decades [11] and is highly associ-
ated to multimorbidity [8].
In a world with an ageing population, the burdens of multimorbidity and polyphar-
macy have undue individual and system-wide impacts on health. While there exists a
growing amount of literature regarding multimorbidity and polypharmacy, the vast major-
ity of studies analyze polypharmacy as descriptive drugs in multimorbidity patterns, focus
almost exclusively on one topic or the other without meaningfully connecting the two, or
examine the disease rather than the individual as the unit of analysis [15–17]. Furthermore,
medication is considered a proxy variable to disease [15,18,19], and, for this reason, jointly
analyzing multimorbidity and polypharmacy can produce an overestimation error due to
the fact that people with prevalent diseases such as diabetes or cardiovascular diseases are
treated with many medications for both clinical conditions and risk factors and, for this
reason, are overestimated. To avoid this, drug groups can be analyzed according to their
associated disease, thereby preventing prevalent diseases from being overestimated. This
type of approach would permit a better understanding of the patient groups and, at the
same time, facilitate strategies aimed at prevention, diagnosis, and treatment because it
includes diseases with or without drug treatment.
As far as we understand, little research has been completed regarding methods that
simultaneously analyze the combined patterns of multimorbidity and polypharmacy at
an individual level. Machine-learning soft clustering models are a robust tool capable of
performing such an analysis. Cluster analysis involves assigning individuals to a certain
cluster so that the items (i.e., units of analysis—diseases and drugs) are as similar as
possible, while individuals in different clusters are as least similar as possible. Cluster
identification is based on similarity measures, and their choice is reliant upon the data
and/or the reason for analysis [20]. Hard clustering forces each individual to belong to only
one cluster, while soft clustering (also called fuzzy clustering) grants varying degrees of
membership, thus allowing for the individual to pertain to multiple clusters [20]. The aim
of this study was to determine combined patterns of multimorbidity and polypharmacy
in the Catalan population 65–99 years of age through a machine-learning soft clustering
technique that incorporates the research team’s mapping of chronic disease and drug
associations.
2. Materials and Methods
2.1. Setting, Design, and Population
Catalonia, an autonomous community of Spain, is a Mediterranean region with
7,515,398 reported inhabitants for the year 2012 [21]. Universal health coverage is es-
tablished for residents in Spain by the National Health Service and is implemented in a
decentralized fashion through each of the seventeen autonomous communities [22]. In Cat-
alonia, the Catalan Health Institute (CHI) manages over 283 primary care centers, offering
health services to over six million residents [23].
A cross-sectional study was performed on the baseline year (2012) of a longitudinal
study (2012–2016) using electronic health records (EHRs) in Catalonia. Inclusion criteria
for the cross-sectional study population allowed for individuals 65–99 years of age on
31 December 2011, who survived until 31 December 2012, and had at least one visit to
Int. J. Environ. Res. Public Health 2021, 18, 9216 3 of 22
a CHI-managed primary care center during the longitudinal study period (2012–2016).
No new entries were permitted in the study, and dropouts were due to either death or
transfer to another primary care center outside of CHI governance. A total of 916,619
eligible individuals were included at the baseline year (Figure 1).
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ables were analyzed exclusively within the study period (2012). 
2.3.1. Chronic Diseases and Multimorbidity 
All diseases in the SIDIAP database were coded according to the International Clas-
sification of Diseases, Version 10 (ICD-10). An operational definition for multimorbidity 
was based on the 60 chronic disease categories determined by Calderón-Larrañaga et al. 
in the Swedish National study of Aging and Care in Kungsholmen (SNAC-K) [25]. Each 
chronic disease category was included as an individual binary variable, and multimorbid-
ity was defined via a dichotomous variable as the presence of two or more diagnoses from 
the 60 chronic disease categories. However, only chronic disease categories with ≥2% 
prevalence in the study population were included for final analysis, thus leaving 47 
SNAC-K chronic disease categories in total (Appendix A Table A1). 
2.3.2. Drugs and Classification 
Invoiced drugs recorded in the SIDIAP database included drugs dispensed in phar-
macies. Drugs received in hospital and/or dispensed by a hospital pharmacy and all other 
drugs not subsidized through the national health system were excluded from this study. 
Drugs were coded according to the Anatomical Therapeutic Chemical (ATC) Classifica-
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2.2. Data Source
The Information System for Research in Primary Care (SIDIAP) contains EHRs from
the primary care centers managed by the CHI [24]. The SIDIAP database, in addition to
clinical information, contains demographic, laboratory, and invoiced drug information,
with every datapoint linked to the individual via an anonymous and unique personal
identifier.
2.3. Variables
The SIDIAP database was the single source of information for all variables. All
variables were analyzed exclusively within the study period (2012).
2.3.1. Chronic Diseases and Multimorbidity
All diseases in the SIDIAP database were coded according to the International Classi-
fication of Diseases, V rsion 10 (ICD-10). An operation l definition for multimorbidity was
based the 60 chronic di ease categories determined by Calderón-Larrañaga et al. in the
Swedish National study of Ag ng and Care in Kungsholmen (SNAC-K) [25]. E ch chronic
disease category was included as an divi ual binary variable, a d multimorbidity was
defi ed via di hotomous variable as the presence of two or more diagnoses fro the 60
chronic disease categories. However, only chronic disease categories with ≥2% prevalence
in the study population were included for final analysis, thus leaving 47 SNAC-K c ronic
dise s categories in total (Appendix A Table A1).
2.3.2. Drugs and Classification
Invoiced rugs recorded in the SIDIAP database included drugs dispensed in phar-
macies. Drugs received in hospital and/or dispensed by a hospital pharmacy and all other
drugs not subsidized through the national health system were excluded from this study.
Drugs were coded according to the Anatomical Therapeutic Chemical (ATC) Classification
System, which categorizes drugs through various levels of specificity into groups (hereafter
referred to as “drug categories”) according to the targeted organ/system and their chemical,
pharmacological, and therapeutic properties [26]. Drug categories with ≥1% prevalence
in the study population were included for final analysis. Chronic use for invoiced drugs
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was determined for individuals who were invoiced three or more packages of the same
drug categories during the study period. While not meeting the prevalence or chronic use
criteria, the drug category Other Drugs Affecting Bone Structure and Mineralization (ATC 4th
level code “M05BX”) was added to the study due to its twice-a-year treatment regimen
for chronic diseases. Each drug category was included as an individual binary variable,
and polypharmacy was defined via a dichotomous variable as chronic use in the same
individual for five or more different drug categories (ATC 4th level) from the eighty-nine
drug categories outlined in the following section.
2.3.3. Grouping of Drugs and Mapping to Chronic Diseases
The research team identified 89 different drug categories (ATC 4th level) (Appendix A
Table A2) associated to the 60 chronic disease categories mentioned prior via a thorough
revision of several databases that are well-known international clinical guidelines for each
disease [27–29]. A mapping was done of all 60 SNAC-K chronic disease categories [25] and
89 drug categories. Drug categories were mapped to the SNAC-K chronic disease categories
for which they are prescribed to treat. Chronic disease-drug categories were then created
in the form of dichotomous variables for individuals who were diagnosed with a SNAC-K
chronic disease category and, depending on disease management criteria, invoiced 0, 1,
or 1+ of the mapped drug categories. (For example, the Allergy disease category was
mapped with seven drug categories. An individual would qualify in this category if
diagnosed with a disease pertaining to the Allergy disease category and invoiced at least
one of the seven drug categories). A total of seven of the final 47 SNAC-K chronic diseases
categories require non-pharmacological treatments or treatment with drugs excluded from
this study and, therefore, could not be mapped. The remaining 40 SNAC-K chronic disease
categories were mapped to drug categories, resulting in 29 chronic disease-drug categories
containing ≥ 2% prevalence in the study population (see Appendix A Table A3 for mapping
example; see Supplementary Materials Table S1 for complete mapping process). The
seven chronic disease categories requiring non-pharmacological treatment or treatment
with drugs excluded from this study and the 29 chronic disease-drug categories, all with
prevalence ≥ 2%, were included to determine combined patterns of multimorbidity and
polypharmacy (Figure 2).
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2.3.4. Other Variables
Pertinent demographic data analyzed in the study includes age (measured in years),
sex (female or male), and socioeconomic status (measured by the MEDEA [Mortality
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in Spanish Small Areas and Socioeconomic and Environmental Inequalities] Index via
quintiles from least deprived to most deprived for urban areas, while rural areas were
sorted into an independent category [30]).
2.4. Statistical Analysis
Descriptive statistics were applied to summarize preliminary findings.
Due to the high dimensionality of the SIDIAP database, dimension-reduction tech-
niques were exercised through PCA Mix, an application of principal component analysis
(PCA) for numeric original variables and multiple correspondence analysis (MCA) for
binary variables. This method reduced the size of the database while maintaining the
complexity of the original data. The Karlis–Saporta–Spinaki rule was applied in order to
select the appropriate number of dimensions to preserve [31].
Using the reduced database, the combined multimorbidity and polypharmacy patterns
were determined through a fuzzy c-means (FCM) clustering algorithm [32], incorporating
the twenty-nine chronic disease-drug categories and the seven chronic disease categories
with non-pharmacological treatment or treatment with drugs excluded from this study, all
of which satisfied the prevalence threshold of ≥2% in the study population. To obtain a
range with the ideal number of clusters, validation indices [33] were calculated (Supplemen-
tary Materials Figure S1). The outcome of the FCM clustering algorithm was a determined
number of models with different numbers of clusters in each model, as calculated by the
validation indices. Each model contained varying degrees of disease-medication associ-
ation, and the final model of clusters was determined by the research team according to
clinical relevance.
The clusters were described in two parts: (1) observed/expected ratios (O/E ratios)
were calculated by dividing the prevalence of a chronic disease or chronic disease-drug
category in a specific cluster by the prevalence of the same chronic disease or chronic
disease-drug category in the entire study population; (2) exclusivity was determined by
dividing the number of individuals with a chronic disease or chronic disease-drug category
in a specific cluster by the amount of all individuals with the same chronic disease or
chronic disease-drug category in the entire study population. A threshold of two for the
O/E ratio was set in order for a disease/medication to be considered a relevant part of
a cluster [34,35]. An exclusivity threshold of 30% was a secondary, but not determining,
factor when evaluating the chronic disease or chronic disease-drug categories association
with a cluster.
All analyses were performed in R version 4.0.3 and Stata version 15. Specifically, R
was used to run the PCA mix and FCM clustering algorithm; Stata was used for data
management.
3. Results
Of the 916,619 eligible individuals 65 years and over (women: 57.8%; mean age:
75.4; standard deviation; 7.4), 853,085 (93.1%) satisfied the criteria for multimorbidity, and
457,576 (49.9%) for polypharmacy (Figure 3). The most frequent chronic disease categories
in the population were hypertension (71%), dyslipidemia (50.9%), osteoarthritis and other
degenerative joint diseases (32.8%), obesity (28.7%), and diabetes (25.1%) [Appendix A
Table A1], with a median of six chronic diseases (interquartile range [IQR] 4.0–8.0) per
person. The most prevalent drug categories included proton pump inhibitors (44.3%),
HMG CoA reductase inhibitors (38.2%), anilides (28.4%), platelet aggregation inhibitors,
excluding heparin (35.6%), and benzodiazepine derivatives (20.9%) [Appendix A Table A2],
with a median of 5 drugs (IQR 2.0–8.0) per person.
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Figure 3. Multimorbid and polymedicated individuals in the study aged 65–99 years (n = 91 ,619,
C talonia, 2012).
The authors identified a seven-cluster solution for combined patterns of multimor-
bidity and polypharmacy. Cluster 2 to Cluster 7 contained over 99% multimorbidity in
each cluster and reported higher overrepresentation values (O/E ratio > 2) for at least
one of the chronic disease or chronic disease-drug categories. Characteristics of the study
participants in each cluster are detailed in Appendix A Table A4. Principal results and the
most frequent chronic disease and chronic disease-drug categories by cluster (Table 1) are
highlighted below:
Table 1. Most frequent 15 chronic disease or chronic disease-drug categories in individuals aged 65–99 years by cluster
(n = 916,619, Catalonia, 2012).
Pattern Disease or Disease-Medication Category O O/E Ratio EX
1
Non-Specific
(n = 344,958: 37.63%)
Chronic disease group for solid neoplasms 12.86 0.86 32.37
Chronic disease-drug group for prostate diseases 7.82 0.77 29.11
Chronic disease-drug group for osteoporosis 7.74 0.74 27.74
Chronic disease group for deafness and hearing loss 5.91 0.60 22.58
Chronic disease-drug group for COPD, emphysema, and chronic
bronchitis 4.26 0.53 20.03
Chronic disease-drug group fo esophagus, stomach, and duodenum
diseases 3.77 0.52 19.54
Chronic disease-drug group for thyroid diseases 2.84 0.51 19.34
Chronic disease group f cat ract and lens diseases 8.47 .50 18.65
Chronic disease-drug group for dementia 1.56 0.47 17.61
Chronic disease-drug group for hypertension 26.41 0.46 17.48
Chronic disease group for bradycardias and conduction diseases 1.12 0.40 15.13
Chronic disease-drug group for sleep disorders 2.22 0.39 14.64
Chronic disease group for obesity 11.29 0.39 14.82
Chronic disease-drug group for dyslipidemia 12.32 0.38 14.40
Chronic disease group for chronic pancreas, biliary tract, and
gallbladder diseases 1.09 .37 13.78
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Table 1. Cont.
Pattern Disease or Disease-Medication Category O O/E Ratio EX
2
Diabetes
(n = 178,457: 19.47%)
Chronic disease-drug group for diabetes 39.52 2.15 41.93
Chronic disease-drug group for glaucoma 10.75 1.78 34.65
Chronic disease group for obesity 49.61 1.73 33.68
Chronic disease-drug group for dyslipidemia 55.12 1.71 33.33
Chronic disease-drug group for hypertension 84.37 1.48 28.89
Chronic disease-drug group for thyroid diseases 7.44 1.34 26.17
Chronic disease-drug group for chronic kidney diseases 13.92 1.32 25.69
Chronic disease-drug group for ischemic heart disease 8.52 1.11 21.61
Chronic disease-drug group for cerebrovascular diseases 6.54 1.01 19.69
Chronic disease group for cataract and lens diseases 17.15 1.00 19.54
Chronic disease-drug group for peripheral vascular disease 2.55 1.00 19.47
Chronic disease-drug group for prostate diseases 9.58 0.95 18.46
Chronic disease group for solid neoplasms 14.06 0.94 18.31
Chronic disease group for deafness and hearing loss 8.42 0.85 16.64
Chronic disease group for chronic pancreas, biliary tract, and





(n = 102,750: 11.21%)
Chronic disease-drug group for peripheral neuropathy 9.73 3.08 34.56
Chronic disease-drug group for dorsopathies 24.05 2.88 32.24
Chronic disease-drug group for other musculoskeletal and joint
diseases 22.42 2.73 30.64
Chronic disease-drug group for other genitourinary diseases 8.68 2.44 27.32
Chronic disease-drug group for glaucoma 14.68 2.43 27.25
Chronic disease-drug group for osteoarthritis and other
degenerative joint diseases 41.87 2.16 24.19
Chronic disease group for deafness and hearing loss 19.68 2.00 22.40
Chronic disease-drug group for neurotic, stress-related, and
somatoform diseases 20.38 1.99 22.36
Chronic disease group for cataract and lens diseases 33.75 1.98 22.14
Chronic disease-drug group for depression and mood diseases 23.16 1.86 20.90
Chronic disease-drug group for osteoporosis 18.91 1.80 20.17
Chronic disease-drug group for colitis and related diseases 18.22 1.79 20.09
Chronic disease-drug group for sleep disorders 9.93 1.74 19.51
Chronic disease-drug group for other psychiatric and behavioral
diseases 3.18 1.58 17.71
Chronic disease-drug group for esophagus, stomach, and duodenum
diseases 11.29 1.55 17.41
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Table 1. Cont.






(n = 90,287: 9.85%)
Chronic disease-drug group for other psychiatric and behavioral
diseases 7.42 3.69 36.34
Chronic disease-drug group for neurotic, stress-related, and
somatoform diseases 37.33 3.65 36.00
Chronic disease-drug group for peripheral neuropathy 10.93 3.46 34.09
Chronic disease-drug group for depression and mood diseases 41.75 3.36 33.10
Chronic disease-drug group for dorsopathies 27.22 3.25 32.06
Chronic disease-drug group for other musculoskeletal and joint
diseases 26.65 3.25 32.00
Chronic disease-drug group for other genitourinary diseases 9.81 2.76 27.14
Chronic disease-drug group for sleep disorders 15.07 2.64 26.02
Chronic disease-drug group for osteoarthritis and other
degenerative joint diseases 47.21 2.43 23.97
Chronic disease-drug group for colitis and related diseases 22.46 2.21 21.76
Chronic disease-drug group for osteoporosis 20.89 1.99 19.58
Chronic disease-drug group for esophagus, stomach, and duodenum
diseases 13.80 1.90 18.70
Chronic disease-drug group for thyroid diseases 8.76 1.58 15.60
Chronic disease-drug group for autoimmune diseases 3.12 1.43 14.13




(n = 80,855: 8.82%)
Chronic disease-drug group for peripheral vascular disease 12.02 4.71 41.57
Chronic disease-drug group for ischemic heart disease 29.85 3.89 34.32
Chronic disease-drug group for cerebrovascular diseases 19.34 2.99 26.37
Chronic disease-drug group for heart failure 21.10 2.83 24.94
Chronic disease group for bradycardias and conduction diseases 7.04 2.53 22.33
Chronic disease-drug group for atrial fibrillation 15.98 2.39 21.06
Chronic disease-drug group for other psychiatric and behavioral
diseases 4.63 2.30 20.33
Chronic disease-drug group for chronic kidney diseases 21.85 2.07 18.27
Chronic disease-drug group for COPD, emphysema, chronic bronchitis 15.85 1.98 17.45
Chronic disease-drug group for colitis and related diseases 19.64 1.93 17.04
Chronic disease-drug group for anemia 11.32 1.93 17.00
Chronic disease-drug group for neurotic, stress-related, and
somatoform diseases 18.28 1.79 15.79
Chronic disease-drug group for prostate diseases 17.96 1.78 15.67
Chronic disease-drug group for depression and mood diseases 21.75 1.75 15.45
Chronic disease-drug group for sleep disorders 9.50 1.67 14.69
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Table 1. Cont.





(n = 69,720: 7.61%)
Chronic disease-drug group for atrial fibrillation 40.07 5.99 45.54
Chronic disease-drug group for heart failure 42.57 5.70 43.38
Chronic disease group for bradycardias and conduction diseases 11.50 4.14 31.48
Chronic disease-drug group for inflammatory arthropathies 11.16 3.34 25.41
Chronic disease-drug group for autoimmune diseases 7.07 3.25 24.69
Chronic disease-drug group for anemia 17.61 3.00 22.81
Chronic disease-drug group for chronic kidney diseases 31.24 2.96 22.52
Chronic disease-drug group for COPD, emphysema, chronic
bronchitis 20.53 2.56 19.49
Chronic disease-drug group for ischemic heart disease 17.01 2.22 16.86
Chronic disease-drug group for peripheral vascular disease 5.36 2.10 15.97
Chronic disease group for chronic pancreas, biliary tract, and
gallbladder diseases 4.88 1.64 12.45
Chronic disease-drug group for cerebrovascular diseases 10.29 1.59 12.10
Chronic disease-drug group for colitis and related diseases 15.91 1.56 11.90
Chronic disease-drug group for prostate diseases 14.98 1.48 11.27
Chronic disease-drug group for hypertension 83.43 1.47 11.16
7
Multisystem
(n = 49,592: 5.41%)
Chronic disease group for other digestive diseases 23.29 9.70 52.46
Chronic disease-drug group for dementia 21.63 6.48 35.07
Chronic disease group for chronic pancreas, biliary tract, and
gallbladder diseases 16.95 5.69 30.77
Chronic disease-drug group for autoimmune diseases 10.95 5.03 27.19
Chronic disease-drug group for inflammatory arthropathies 14.80 4.43 23.97
Chronic disease-drug group for anemia 19.82 3.37 18.25
Chronic disease-drug group for atrial fibrillation 14.80 2.21 11.96
Chronic disease-drug group for heart failure 16.37 2.19 11.87
Chronic disease-drug group for colitis and related diseases 19.34 1.90 10.29
Chronic disease-drug group for chronic kidney diseases 19.73 1.87 10.12
Chronic disease group for bradycardias and conduction diseases 4.49 1.61 8.73
Chronic disease-drug group for COPD, emphysema, chronic bronchitis 12.50 1.56 8.44
Chronic disease-drug group for cerebrovascular diseases 10.06 1.55 8.41
Chronic disease-drug group for esophagus, stomach, and duodenum
diseases 9.95 1.37 7.41
Chronic disease-drug group for osteoarthritis and other degenerative
joint diseases 25.47 1.31 7.10
Categories highlighted in gray are chronic disease categories; those in white are chronic disease-drug categories. Categories in bold reach
the O/E ratio threshold of two. Abbreviations: O: disease prevalence in the cluster; O/E ratio: observed/expected ratio; Ex: exclusivity;
COPD: chronic obstructive pulmonary disease.
Cluster 1 (non-specific) included a substantial number of individuals that do not
present any overrepresented chronic disease or chronic disease-drug category (O/E ratios
are below two and exclusivity values are below 30%). Cluster 1 was also the cluster with
the lowest average age (74.20 years, SD 7.47) and the lowest percentage of individuals with
multimorbidity (81.74%) and polypharmacy (15.38%).
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Diabetes (Cluster 2): The only category that surpassed the O/E ratio threshold was
chronic disease-drug group for “diabetes” (O/E ratio 2.15), with exclusivity of 41.93%.
Neurological and musculoskeletal, female dominant (Cluster 3): 69.05% of the indi-
viduals in this cluster were female, with exclusivity for the chronic disease-drug groups for
“peripheral neuropathy”, “dorsopathies”, and “other musculoskeletal and joint diseases”
all surpassing 30%. Similar to Cluster 3 is behavioral, neurological, and musculoskeletal,
female dominant (Cluster 4), which also has a high proportion of females (75.08%) and
contains many of the chronic disease-drug groups from the neurological and musculoskele-
tal categories. However, the differentiating factor is the emphasis on behavioral chronic
disease-drug groups, with several groups pertaining to this category as well.
Cardio-cerebrovascular and renal (Cluster 5): The vast majority (six out of eight) of
the significant groups in this cluster are cardiovascular related, with exclusivity of chronic
disease-drug groups for “peripheral vascular disease” and “ischemic heart disease” both
exceeding 30%. This cluster contained the highest proportion of polypharmacy (83.65%).
Cardiovascular, renal, inflammatory, and respiratory (Cluster 6): Cardiovascular
categories occupy the top three spots, with chronic disease-drug categories for “atrial
fibrillation” (O/E ratio 5.99) and “heart failure” (O/E ratio 5.70), and chronic disease
category “bradycardias and conduction disorders” (O/E ratio 4.14), all exceeding an
exclusivity of 30%. This cluster contained the highest proportions for individuals diagnosed
with 10 or more chronic diseases (30.82%), individuals prescribed 10 or more chronic drugs
(27.71%), and individuals with 10 or more primary care visits (75.38%). Polypharmacy was
nearly that of Cluster 5 (83.54%).
The multisystem pattern identified in Cluster 7 represents the smallest group of indi-
viduals from the study population (5.41%) and contains several overrepresented diseases
corresponding to multiple systems, in which individuals with digestive disease dominate
the cluster.
Socioeconomic status (measured by MEDEA index) between categories appears to
remain relatively stable in Cluster 2 to Cluster 7, with most deprived fluctuating between
13.63–15.79% and least deprived between 14.90–16.57%. Those in rural health settings
fluctuate between 19.34–23.83% in Cluster 2 to Cluster 7.
4. Discussion
4.1. Key Results
In this article, patterns for multimorbidity and polypharmacy were analyzed in a joint
manner by means of creating a variable relating each drug to one or more diseases for which
they are indicated. Such patterns were obtained via specified criteria that allowed for the
identification of multimorbid individuals that also qualified as polymedicated (those who
were invoiced more than five distinct drugs in one year). This study ultimately identified
distinct patterns with singular characteristics, with some more profound in women than in
men. This is a key point in order to carry out a stricter follow up of the individuals who
have a higher risk of presenting secondary effects caused by drugs or drug interaction.
Cluster 1 (non-specific) did not overrepresent any disease and Cluster 7 (multisys-
temic) overrepresented diseases from many systems are less specific than Clusters 2 to 6.
These cluster types have been identified in other studies [35,36]. In our study, we were
able to identify overrepresented diseases that do not have any prescribed drug in primary
healthcare, such as neoplastic disease, deafness and hearing loss, and bradycardias and
conduction diseases. These data suggest that diseases and drugs should be considered in
combination to more efficiently identify multimorbidity patterns [37].
It was observed that the chronic disease-drug categories “hypertension” and “dys-
lipidemia” are distributed throughout the seven obtained clusters. Individuals with these
common pathologies are therefore not grouped together in any one specific cluster; rather,
they are spread throughout all seven. The fuzzy c-means method is a technique that
classifies individuals based on cluster probability membership, and, given that there were
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many individuals with these chronic diseases and associated drugs in the study, the results
are homogenously distributed throughout the study population [37].
The patterns from Cluster 2 to Cluster 6 group individuals who share similar chronic
disease-drug categories. Cluster 2 is classified as diabetes because 41.93% of individuals
included in the cluster are diabetic. Although not reaching the O/E threshold of two,
associations are still observed between diabetes and obesity, cataracts, and neoplasms, all
diseases that are frequently presented in diabetic individuals [38–40].
Cluster 3 (neurological and musculoskeletal) and Cluster 4 (behavioral, neurological,
and musculoskeletal) include patterns predominantly in women. The clustering model
identified these two groups of individuals that present similar health problems with
singular characteristics. The patterns within behavioral, neurological, and musculoskeletal
show an association with autoimmune diseases that are also more frequent in women [41].
Cluster 5 (cardio-cerebrovascular and renal) and Cluster 6 (cardiovascular, renal, in-
flammatory, and respiratory) include chronic disease-drug patterns that primarily treat
cardiac, cardiovascular, cerebrovascular, and renal pathologies. This association, which
has been observed in a previous study that indicated a pattern of increased mortality [16],
concerns closely related pathologies that also share risk factors and even treatments. This
study allows for the grouping of individuals with similar chronic disease and chronic
disease-drug categories into two differentiated and specific clusters, given that Cluster 6
(cardiovascular, renal, inflammatory, and respiratory) includes a chronic disease-drug cate-
gory for inflammatory pathologies as well as a chronic disease-drug group for respiratory
diseases. Chronic inflammation as a mechanism in atherosclerosis carries a higher risk for
cardiovascular and cerebrovascular events [42]. Autoimmune diseases and arthrosis have
also been linked to an increase in cardiovascular disease, although this could be due to
adverse effects of the treatments for these diseases, such as corticoids [43,44].
A small group of individuals who presented polypharmacy did not satisfy the con-
dition for multimorbidity. This could be due to the individuals having received multiple
treatments during the study period without them coinciding. On the other hand, there
is also the possibility that some pathologies could be treated with five or more drugs
simultaneously for certain patients, with neuropathy being a prime example.
The inclusion of the same study variable for chronic diseases and drugs indicated for
their respective diseases’ treatment is an advantage that allows for a better identification
of the individuals and, thereby, allows to better orient the clinical management of these
groups of individuals.
The methodology used for mapping drugs and chronic diseases permitted the iden-
tification of a new chronic diseases-drug category. This new variable applied to fuzzy
clustering methods is less susceptible to outliers in the data, choice of distance measure,
and the inclusion of inappropriate or irrelevant variables [35,45,46].
This mapping process between chronic diseases and drugs, together with the applica-
tion of the fuzzy method, will be very useful for multimorbidity studies where drugs are
used as a proxy variable.
Soft clustering methods offer a new methodological approach towards understanding
the relationships between specific diseases or drugs in individuals. This is an essential
step in improving the care of patients and the quality of health systems. Analyzing
multimorbidity patterns based on drugs permits the identification of patient subgroups
with different clinical approaches and attention. Our analysis focuses on groups of patients
with specific diseases and drugs as opposed to other studies centered in diseases.
This methodology can be applied in a large variety of studies using electronic health
records to study polypharmacy and multimorbidity.
4.2. Comparison to the Literature
Studies performed with clustering methods concerning multimorbidity and polyphar-
macy are novel but becoming more frequent [47]; however, these studies generally approach
multimorbidity with a polypharmacy perspective or vice versa. To the authors’ knowledge,
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this study is the first in conveying a combined approach to multimorbidity and polyphar-
macy by combining both topics into one inclusive variable to determine joint outcomes.
Although, as previously mentioned, some of the patterns obtained (neurological and
musculoskeletal, female dominant; behavioral, neurological, and musculoskeletal, female
dominant; and cardio-cerebrovascular and renal) coincide with the literature [17,37,48].
4.3. Strengths and Limitations
The sample size, with nearly one million individuals, is a clear advantage of the study.
Considering individuals as the primary variable for analysis rather than diseases [34], the
study employs a large, high-quality database composed of primary health care records
representative of the Catalan population aged ≥ 65 years [24], an age group that is more
susceptible to present health problems related to drugs. The inclusion of all drugs that
are indicated for different diseases with a minimum number of packages facilitates the
identification of those individuals who should be more thoroughly monitored. Regarding
the method, soft clustering offers a methodologic focus in understanding the relations be-
tween specific diseases and individuals. The analysis of multimorbidity and polypharmacy
patterns can identify subgroups of patients with different associated diseases and drugs.
The extensive mapping process of drug categories to their respective SNAC-K chronic
disease categories provides a further level of detail than most other clustering techniques
within the literature. This can ultimately serve as a framework for future studies that wish
to map diseases and drugs under certain conditions to determine combined patterns.
Some limitations of this study should be considered. Individuals who met initial
selection criteria but sought care outside of CHI governance were ineligible, possibly
introducing selection bias for individuals who chose to seek care in a private healthcare
facility. However, this is a small group of the population, and the results of this study
can be applied to the general population. Drugs were recorded via invoices, and hospital
drugs were not included, which could have influenced the calculation for polypharmacy.
Concerning the clusters, the results obtained in this study are similar to those obtained
in other studies without prior mapping; nevertheless, we consider that this methodology
more precisely determines which pathologies and drugs are overrepresented in each cluster,
thus more adequately defining patient profiles. Finally, while the fuzzy c-means clustering
technique used in this study is an unsupervised, exploratory method, the authors believe
that, combined with a vigorous internal validation system, this technique produces robust
results and minimizes potential pitfalls.
5. Conclusions
This study utilized a mapping process combined with a soft clustering technique to
determine combined patterns of multimorbidity and polypharmacy in the elderly Catalan
population in 2012, identifying overrepresentation in 6 of the 7 clusters with chronic disease
and chronic disease-drug categories. Cluster 2 to Cluster 6 provided recognizable patterns,
predominantly in diabetes; neurological and musculoskeletal, female dominant and behav-
ioral, neurological, and musculoskeletal, female dominant; and cardio-cerebrovascular and
renal and cardiovascular, renal, inflammatory, and respiratory. These patterns further high-
light the differences between sexes, specifically within neurological and musculoskeletal,
female dominant and behavioral, neurological, and musculoskeletal, female dominant.
The combined patterns of multimorbidity and polypharmacy identified in this study
will contribute key information to the evaluation of multimorbid and polymedicated indi-
viduals, facilitating the identification of these subgroups of individuals that require specific
attention. The obtained results could be applied to clinical practice guidelines differen-
tiating distinct population groups, such as multimorbid individuals with and without
associated diseases and/or polypharmacy. Due to the relationship between multimorbidity
and polypharmacy over long periods of time, this analysis could serve as the base to deepen
this relationship in further longitudinal studies. The patterns obtained in this research will
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allow for an in-depth study of the prescription of multiple medications in elderly people in
relation to medication-related problems.
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Appendix A
Table A1. Prevalence of the 60 chronic diseases included in the study in individuals aged 65–99 years (n = 916,619, Catalonia,
2012). In the last column, list of diseases included by prevalence cut off of 2%.
Rank Chronic Conditions Frequency Percentage (%) Cut Off of 2%
1 Hypertension 650,899 71.0
2 Dyslipidemia 466,585 50.9
3 Osteoarthritis and other degenerative joint diseases 300,803 32.8
4 Obesity 262,888 28.7
5 Diabetes 230,460 25.1
6 Anemia 167,577 18.3
7 Cataract and other lens diseases 156,622 17.1
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Table A1. Cont.
Rank Chronic Conditions Frequency Percentage (%) Cut Off of 2%
8 Chronic kidney diseases 153,756 16.8
9 Prostate diseases 153,635 16.8
10 Osteoporosis 151,847 16.6
11 Depression and mood diseases 148,751 16.2
12 Solid neoplasms 137,045 15.0
13 Colitis and related diseases 131,512 14.4
14 Venous and lymphatic diseases 126,997 13.9
15 Other musculoskeletal and joint diseases 124,765 13.6
16 Dorsopathies 124,603 13.6
17 Neurotic, stress-related and somatoform diseases 123,395 13.5
18 COPD, emphysema, chronic bronchitis 109,603 12.0
19 Ischemic heart disease 95,434 10.4
20 Deafness, hearing impairment 90,261 9.9
21 Sleep disorders 88,739 9.7
22 Thyroid diseases 88,445 9.7
23 Other genitourinary diseases 85,468 9.3
24 Cerebrovascular disease 80,264 8.8
25 Atrial fibrillation 80,247 8.8
26 Esophagus, stomach and duodenum diseases 80,043 8.7
27 Heart failure 74,077 8.1
28 Other eye diseases 68,939 7.5
29 Glaucoma 66,162 7.2
30 Inflammatory arthropathies 62,450 6.8
31 Dementia 59,213 6.5
32 Cardiac valve diseases 52,100 5.7
33 Peripheral neuropathy 49,127 5.4
34 Other psychiatric and behavioral diseases 46,841 5.1
35 Asthma 43,663 4.8
36 Allergy 40,394 4.4
37 Autoimmune diseases 39,350 4.3
38 Ear, nose, throat diseases 38,752 4.2
39 Peripheral vascular disease 30,674 3.4
40 Other neurological diseases 28,541 3.1
41 Chronic pancreas, biliary tract and gallbladder diseases 27,321 3.0
42 Migraine and facial pain syndromes 25,999 2.8
43 Bradycardias and conduction diseases 25,476 2.8
44 Chronic liver diseases 22,633 2.5
45 Other digestive diseases 22,022 2.4
46 Parkinson and parkinsonism 20,833 2.3
47 Other metabolic diseases 18,997 2.1
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Table A1. Cont.
Rank Chronic Conditions Frequency Percentage (%) Cut Off of 2%
48 Other cardiovascular diseases 16,833 1.8
49 Other skin diseases 15,363 1.7
50 Chronic ulcer of the skin 13,869 1.5
51 Blood and blood forming organ diseases 13,575 1.5
52 Other respiratory diseases 9974 1.1
53 Epilepsy 8981 1.0
54 Hematological neoplasms 8174 0.9
55 Chronic infectious diseases 6647 0.7
56 Inflammatory bowel diseases 5549 0.6
57 Schizophrenia and delusional diseases 4792 0.5
58 Blindness, visual impairment 4772 0.5
59 Multiple sclerosis 576 0.1
60 Chromosomal abnormalities 77 0.0
Abbreviations: COPD: chronic obstructive pulmonary disease. The black shading in the lower part of the table IS necessary, as it indicates a
cut off of 2%, as defined in the first line.
Table A2. Prevalence of the 89 medication categories diseases included in the study in individuals aged 65–99 years
(n = 916,619, Catalonia, 2012).
Rank ATC-5 Code Medication Categories Frequency Percentage (%)
1 A02BC Proton pump inhibitors 405,942 44.29
2 C10AA HMG CoA reductase inhibitors 349,676 38.15
3 N02BE Anilides 260,018 28.37
4 B01AC Platelet aggregation inhibitors excl. heparin 234,306 25.56
5 N05BA Benzodiazepine derivatives 191,870 20.93
6 C09AA ACE inhibitors, plain 182,906 19.95
7 A10BA Biguanides 119,955 13.09
8 C08CA Dihydropyridine derivatives 116,713 12.73
9 N06AB Selective serotonin reuptake inhibitors 116,497 12.71
10 C07AB Beta blocking agents, selective 102,442 11.18
11 C03CA Sulfonamides, plain 101,933 11.12
12 C09CA Angiotensin II antagonists, plain 99,742 10.88
13 A12AX Calcium, combinations with vitamin D and/or other drugs 93,581 10.21
14 C03AA Thiazides, plain 86,414 9.43
15 C09DA Angiotensin II antagonists and diuretics 80,115 8.74
16 M01AE Propionic acid derivatives 79,393 8.66
17 C09BA ACE inhibitors and diuretics 74,494 8.13
18 G04CA Alpha-adrenoreceptor antagonists 71,028 7.75
19 B01AA Vitamin K antagonists 62,331 6.80
20 M05BA Bisphosphonates 62,313 6.80
21 R03BB Anticholinergics 53,159 5.80
22 N05CD Benzodiazepine derivatives 52,859 5.77
23 A10BB Sulfonylureas 50,812 5.54
24 H03AA Thyroid hormones 50,699 5.53
25 R03AK Adrenergics in combination with corticosteroids or otherdrugs, excl. anticholinergics 50,644 5.53
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Rank ATC-5 Code Medication Categories Frequency Percentage (%)
26 N02AX Other opioids 48,388 5.28
27 M04AA Preparations inhibiting uric acid production 47,629 5.20
28 N06AX Other antidepressants 45,357 4.95
29 R03AC Selective beta-2-adrenoreceptor agonists 43,972 4.80
30 S01ED Beta blocking agents 42,513 4.64
31 C01DA Organic nitrates 41,674 4.55
32 S01EE Prostaglandin analogues 40,643 4.43
33 N03AX Other antiepileptics 37,873 4.13
34 B03AA Iron bivalent, oral preparations 35,13 3.83
35 M01AX Other anti-inflammatory and antirheumatic agents,non-steroids 34,490 3.76
36 M01AB Acetic acid derivatives and related substances 30,848 3.37
37 N02BB Pyrazolones 30,600 3.34
38 C02CA Alpha-adrenoreceptor antagonists 26,333 2.87
39 N07CA Antivertigo preparations 25,290 2.76
40 C01EB Other cardiac preparations 24,272 2.65
41 G04BD Drugs for urinary frequency and incontinence 23,646 2.58
42 D01AC Imidazole and triazole derivatives 23,459 2.56
43 A03FA Propulsives 22,461 2.45
44 A10AE Insulins and analogues for injection, long-acting 21,678 2.36
45 H02AB Glucocorticoids 21,493 2.34
46 C01AA Digitalis glycosides 21,190 2.31
47 D07AC Corticosteroids, potent (Group III) 20,599 2.25
48 G04CB Testosterone-5-alpha reductase inhibitors 19,379 2.11
49 N06DA Anticholinesterases 19,366 2.11
50 C08DB Benzothiazepine derivatives 19,211 2.10
51 R03BA Glucocorticoids 19,143 2.09
52 R06AX Other antihistamines for systemic use 18,609 2.03
53 C07AG Alpha and beta blocking agents 18,198 1.99
54 A02BA H2-receptor antagonists 18,158 1.98
55 C03BA Sulfonamides, plain 17,998 1.96
56 C10AB Fibrates 17,874 1.95
57 N05CF Benzodiazepine related drugs 17,914 1.95
58 G03CA Natural and semisynthetic estrogens, plain 16,513 1.80
59 C03DA Aldosterone antagonists 16,367 1.79
60 N06DX Other anti-dementia drugs 16,292 1.78
61 A10BD Combinations of oral blood glucose lowering drugs 15,397 1.68
62 N06AA Non-selective monoamine reuptake inhibitors 15,364 1.68
63 N05AH Diazepines, oxazepines, thiazepines and oxepines 14,249 1.55
64 R01AD Corticosteroids 13,880 1.51
65 G04CX Other drugs used in benign prostatic hypertrophy 13,684 1.49
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Rank ATC-5 Code Medication Categories Frequency Percentage (%)
66 J01MA Fluoroquinolones 13,610 1.48
67 C03EA Low-ceiling diuretics and potassium-sparing agents 13,179 1.44
68 A10BX Other blood glucose lowering drugs, excl. insulins 12,933 1.41
69 A12AA Calcium 12,809 1.40
70 C09DB Angiotensin II antagonists and calcium channel blockers 12,698 1.39
71 A12BA Potassium 12,625 1.38
72 J01CR Combinations of penicillins, incl. beta-lactamase inhibitors 12,658 1.38
73 C04AD Purine derivatives 12,589 1.37
74 C10AX Other lipid modifying agents 12,579 1.37
75 M01AH Coxibs 12,537 1.37
76 N04BA Dopa and dopa derivatives 12,280 1.34
77 D01AE Other antifungals for topical use 11,514 1.26
78 A11CC Vitamin D and analogues 11,262 1.23
79 A10AD Insulins and analogues for injection, intermediate- orlong-acting combined with fast-acting 11,056 1.21
80 A10AC Insulins and analogues for injection, intermediate-acting 10,925 1.19
81 N02AB Phenylpiperidine derivatives 10,802 1.18
82 B03BA Vitamin B12 (cyanocobalamin and analogues) 10,613 1.16
83 C01BD Antiarrhythmics, class III 10,511 1.15
84 N05AX Other antipsychotics 10,404 1.14
85 C07AA Beta blocking agents, non-selective 10,231 1.12
86 S01EC Carbonic anhydrase inhibitors 9737 1.06
87 B03AB Iron trivalent, oral preparations 9504 1.04
88 N03AE Benzodiazepine derivatives 9211 1.00
89 M05BX Other drugs affecting bone structure and mineralization 7652 0.83
Abbreviations: HMGCoA-reductase: 3-Hidroxi-3-metil-glutaril-CoA reductase; ACE inhibitors: angiotensin converting enzyme inhibitors.
Table A3. Mapping of SNAC-K chronic disease categories and their associated ATC drugs categories (first two categories).
ALLERGY
ICD-10 codes and labels included in chronic disease category ATC-5 codes and labels for drugs associated to chronic diseasecategory. Includes none or any of the following:
J301 Allergic rhinitis due to pollen R01AD Corticosteroids (nasal use)
J302 Other seasonal allergic rhinitis R03AC Selective beta-2-adrenoreceptor agonists
J303 Other allergic rhinitis R03AK Adrenergics in combination with corticosteroidsor other drugs, excl. anticholinergics
J304 Allergic rhinitis, unspecified R03BA Glucocorticoids (inhalation)
J450 Predominantly allergic asthma R03BB Anticholinergics
K522 Allergic and dietetic gastroenteritis and colitis R06AX Other antihistamines for systemic use
L20 Atopic dermatitis D07AC Corticosteroids, potent (Group III) (topical use)
L23 Allergic contact dermatitis
L500 Allergic urticaria
Z516 Desensitization to allergens
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ANEMIA
ICD-10 codes and labels included in chronic disease category ATC-5 codes and labels for drugs associated to chronic diseasecategory. Includes none or any of the following:
D50 Iron deficiency anaemia B03AA Iron bivalent, oral preparations
D51 Vitamin B12 deficiency anaemia B03AB Iron trivalent, oral preparations
D52 Folate deficiency anaemia B03BA Vitamin B12 (cyanocobalamin and analogues)
D53 Other nutritional anaemias H02AB Glucocorticoids (systemic use, plain)
D55 Anaemia due to enzyme disorders
D56 Thalassaemia
D57 Sickle-cell disorders
D58 Other hereditary haemolytic anaemias
D59 Acquired haemolytic anaemia
D60 Acquired pure red cell aplasia[erythroblastopenia]
D61 Other aplastic anaemias
D63 Anaemia in chronic diseases classified elsewhere
D64 Other anaemias
Only chronic diseases and their associated ATC drug categories resulting in chronic disease or chronic disease-drug categories ≥ 2%
prevalence are included in this table. For the sake of brevity, only the first two mapped categories are shown. The complete mapping table
can be found in Supplementary Materials Table S1. Remaining categories with <2% prevalence can be sent to readers upon request.
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Table A4. Variables characterizing each cluster for chronic disease or chronic disease-drug category threshold of 2% (n = 916,619).















7. Multisystem Study Population(All)
Number of people, n 344,958 178,457 102,750 90,287 80,855 69,720 49,592 916,619
Multimorbidity, n (%) 281,952 (81.74) 178,412 (99.97) 102,629 (99.88) 90,245 (99.95) 80,819 (99.96) 69,680 (99.94) 49,347 (99.51) 853,084 (93.07)
Polypharmacy, n (%) 53,070 (15.38) 105,323 (59.02) 69,503 (67.64) 68,276 (75.62) 67,635 (83.65) 58,245 (83.54) 35,523 (71.63) 457,575 (49.92)
Women, n (%) 187,691 (54.41) 98,251 (55.06) 70,946 (69.05) 67,785 (75.08) 39,649 (49.04) 35,130 (50.39) 29,679 (59.85) 529,131 (57.73)
Men, n (%) 157,267 (45.59) 80,206 (44.94) 31,803 (30.95) 22,502 (24.92) 41,207 (50.96) 34,590 (49.61) 19,913 (40.15) 387,488 (42.27)
Age, mean (SD) 74.28 (7.47) 74.61 (6.86) 75.82 (7.07) 75.43 (7.06) 77.06 (7.34) 78.47 (7.30) 78.27 (7.52) 75.41 (7.39)
Age (categories), n (%)
[65,70) 119,921 (34.76) 51,741 (28.99) 24,050 (23.41) 23,121 (25.61) 15,649 (19.35) 9796 (14.05) 7901 (15.93) 252,178 (27.51)
[70,80) 140,724 (40.79) 83,142 (46.59) 47,314 (46.05) 41,082 (45.5) 34,708 (42.93) 28,197 (40.44) 19,419 (39.16) 394,586 (43.05)
[80,90) 71,317 (20.67) 39,345 (22.05) 27,970 (27.22) 23,398 (25.92) 26,574 (32.87) 27,204 (39.02) 18,936 (38.18) 234,744 (25.61)
[90,99] 12,997 (3.77) 4229 (2.37) 3416 (3.32) 2686 (2.97) 3924 (4.85) 4524 (6.49) 3336 (6.73) 35,111 (3.83)
MEDEA * index, n (%)
R 71,007 (21.98) 35,761 (21.22) 18,739 (19.54) 16,239 (19.34) 15,426 (21.01) 14,514 (23.28) 10,563 (23.83) 182,249 (19.88)
U1 63,526 (19.67) 25,114 (14.90) 14,580 (15.20) 13,131 (15.64) 11,684 (15.91) 9413 (15.10) 7344 (16.57) 144,792 (15.80)
U2 53,337 (16.51) 26,606 (15.79) 15,239 (15.89) 13,307 (15.85) 11,546 (15.72) 9563 (15.34) 6832 (15.41) 136,430 (14.88)
U3 51,420 (15.92) 28,004 (16.62) 15,988 (16.67) 13,976 (16.64) 11,928 (16.24) 9839 (15.78) 7068 (15.94) 138,223 (15.08)
U4 46,598 (14.43) 28,059 (16.65) 16,264 (16.96) 14,066 (16.75) 11,795 (16.06) 9726 (15.60) 6480 (14.62) 132,988 (14.51)
U5 37,128 (11.49) 24,998 (14.83) 15,109 (15.75) 13,264 (15.79) 11,050 (15.05) 9290 (14.90) 6043 (13.63) 116,882 (12.75)
Number of chronic
diseases, median [IQR] 3 [2–5] 6 [4–7] 7 [5–9] 8 [6–10] 8 [6–10] 8 [6–10] 7 [6–10] 6 [4–8]
Number of chronic
diseases (categories), n (%)
0 25,380 (7.36) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 25,380 (2.77)
1 37,626 (10.91) 45 (0.03) 121 (0.12) 42 (0.05) 36 (0.04) 40 (0.06) 244 (0.49) 38,154 (4.16)
[2,5) 176,529 (51.17) 50,912 (28.53) 12,934 (12.59) 7896 (8.75) 7990 (9.88) 6133 (8.8) 6441 (12.99) 268,836 (29.33)
[5,10) 99,930 (28.97) 114,840 (64.35) 67,586 (65.78) 58,154 (64.41) 51,082 (63.18) 42,058 (60.32) 30,059 (60.61) 463,709 (50.59)
≥10 5493 (1.59) 12,660 (7.09) 22,109 (21.52) 24,195 (26.8) 21,747 (26.9) 21,489 (30.82) 12,847 (25.91) 120,540 (13.15)
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Table A4. Cont.















7. Multisystem Study Population(All)
Number of medications,
median [IQR] 2 [0–3] 5 [3–7] 6 [4–8] 6 [5–9] 7 [5–9] 7 [5–10] 6 [4–9] 4 [2–7]
Number of medications,
(categories), n (%)
0 113,702 (32.96) 536 (0.3) 1414 (1.38) 132 (0.15) 24 (0.03) 180 (0.26) 1801 (3.63) 117,789 (12.85)
1 50,694 (14.7) 5232 (2.93) 3057 (2.97) 1282 (1.42) 581 (0.72) 602 (0.86) 1364 (2.75) 62,812 (6.85)
[2,5) 127,492 (36.96) 67,366 (37.75) 28,777 (28.01) 20,597 (22.81) 12,615 (15.6) 10,692 (15.34) 10,904 (21.99) 278,442 (30.38)
[5,10) 50,510 (14.64) 90,914 (50.94) 55,102 (53.63) 52,401 (58.04) 47,710 (59.01) 38,927 (55.83) 25,494 (51.41) 361,058 (39.39)
≥10 2560 (0.74) 14,410 (8.07) 14,401 (14.02) 15,875 (17.58) 19,924 (24.64) 19,318 (27.71) 10,029 (20.22) 96,518 (10.53)
Number of visits 2012,
median [IQR] 6 [2–10] 10 [6–16] 12 [7–18] 12 [7–19] 14 [8–23] 18 [10–29] 13 [7–23] 9 [5–16]
Number of visits 2012
(categories), n (%)
0 44,954 (13.03) 825 (0.46) 637 (0.62) 317 (0.35) 242 (0.3) 204 (0.29) 766 (1.54) 47,945 (5.23)
1 25,389 (7.36) 3155 (1.77) 1463 (1.42) 1213 (1.34) 1026 (1.27) 683 (0.98) 954 (1.92) 33,884 (3.7)
[2,5) 75,895 (22) 20,685 (11.59) 9889 (9.62) 8168 (9.05) 6708 (8.3) 4336 (6.22) 4759 (9.6) 130,439 (14.23)
[5,10) 101,438 (29.41) 56,518 (31.67) 27,564 (26.83) 22,805 (25.26) 18,077 (22.36) 11,938 (17.12) 11,008 (22.2) 249,349 (27.2)
≥10 97,283 (28.2) 97,274 (54.51) 63,197 (61.51) 57,783 (64) 54,802 (67.78) 52,558 (75.38) 32,105 (64.74) 455,002 (49.64)
For the sake of simplicity, all numbers in the table were rounded to its closest natural number. * MEDEA index starts with U1 (urban setting, least deprived) and ends with U5 (urban setting, most deprived).
Individuals in rural settings are classified in the variable R. MEDEA index n = 851,564.
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